Autologous hematopoietic stem cell transplantation for multiple sclerosis: A current perspective

Area of Science:

• Neurology
• Immunology
• Hematology

Background:

• Highly active multiple sclerosis (MS) requires potent treatments to control inflammation.
• Autologous hematopoietic stem cell transplantation (AHSCT) is the most effective therapy for halting MS inflammation.
• Advances in patient selection and supportive care have improved AHSCT safety.

Purpose of the Study:

• To identify comorbidities and prior therapies that increase AHSCT risks in MS patients.
• To determine the optimal AHSCT conditioning regimen balancing efficacy and safety.
• To clarify the role of AHSCT within the broader MS treatment landscape.

Main Methods:

• Review of current clinical practices and ongoing research in AHSCT for MS.
• Analysis of data from patient registries and clinical trials.
• Comparison of AHSCT outcomes with advanced disease-modifying therapies.

Main Results:

• AHSCT demonstrates significant efficacy in halting inflammation in highly active MS.
• Improved safety profiles observed due to better patient selection and conditioning regimens.
• Further research is needed to fully elucidate risk factors and optimal AHSCT protocols.

Conclusions:

• AHSCT is a valuable, established treatment for select MS patients.
• Continued research and comparative studies are essential for optimizing AHSCT's place in MS management.
• Understanding risk factors and refining AHSCT protocols will enhance its long-term safety and efficacy.